TABLE 1.

Patients' characteristics and outcomes, and comparison with the general psoriatic population at our clinic in the time analyzed

No. of patients	Age	Sex	BMI	Age of onset	Type of Psoriasis	PSA	Bilogic in course	Previous biological therapy	PASI at baseline	PASI 16w	PASI 90 16w	PASI100W	PASI a 28settimane	PASI90 28 W	PASI 10028 W	PASI 40 W	PASI90 40 W	PASI 10040 W	PASI 52 W	PASI90 52 W	PASI 10052 W	Follow up (months)	Cause of IL23inhibitors suspension	Obesity	Cardiovascular disease	Diabetes Mellitus
1	62	1	27	46	Vulgar	No	Brodalumab	Ixekizumab, risankizumab	8	0	Yes	Yes	0	Yes	Yes	2	No	No				5	Prior inefficacy, adverseevent	No	Yes	No
2	66	0	25	4	Vulgar	Yes	Brodalumab	Ixekizumab, guselkumab	8	0	No	No	0	Yes	Yes	2	No	No	0	Yes	Yes	5	Second inefficacy	No	No	No
3	51	1	28	26	Vulgar	No	Ixekizumab	Secukinumab, ixekizumab, guslkumab	6	0	Yes	Yes	0	Yes	Yes	0	Yes	Yes	0	Yes	Yes	6	Prior inefficacy,	No	No	No
4	34	0	20	18	Vulgar, inverse	No	Brodalumab	Guselkumab	14	5	No	No	5	No	No	5	No	No	5	No	No	12	Second inefficacy	No	No	No
5	22	0	29	16	Vulgar	No	Brodalumab	Guselkumab	7	0	Yes	Yes	0	Yes	Yes	0	Yes	Yes				6	Prior inefficacy	No	No	No
6	45	0	21	11	Vulgar	Yes	Ixekizumab	Guselkumab	5	0	Yes	Yes	0	Yes	Yes	1	No	No				10	Prior inefficacy	No	No	No
7	61	0	25	55	Pustolar	Yes	Ixekizumab	Ustekinumab, guselkumab	10	3	No	No	3	No	No	0	Yes	Yes				7	Prior inefficacy	No	Yes	No
							Switched patients (7)						General population (783)									p‐value
Sex (F/M)							71.4%						35.5%									0.104
Age (mean)							48.7						52.2									0.886
Age of onset (mean)							25.1						34.3									0.947
PSA (yes/no)							42.8%						28.7%									0.475
BMI (mean)							25						27									0.225
Obesity (yes/no)							0%						23.8%									1
Cardiovascular disease (yes/no)							28.6%						44%									0.475
Diabetes Mellitus (yes/no)							0%						12.7%									1

Abbreviation: PASI, Psoriasis severity index.